Key facts
- It has raised $20.3M across 1 recorded rounds; the latest was Early Stage VC ($9.8M) in Oct 2024.
- Notable investors include WARF Ventures, Wisconsin Alumni Research Foundation, Bluestem Capital Company, Visionary Venture Fund.
- Hubble Therapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($9.8M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Hubble Therapeutics
Funding rounds
1 roundsAbout Hubble Therapeutics
Developer of a gene therapy platform designed for a rare genetic eye disorder that typically presents with severe progressive visual impairment. The company's proprietary gene therapy treats leber congenital amaurosis, a rare genetic eye disorder, enabling patients to reverse that loss and restore sight with a single treatment.
- Sector
- Healthcare
- HQ
- Hanover, NH, United States
- Founded
- 2000
- Employees
- 2
- Website
- hubbletx.com/
- Ownership
- Privately Held (backing)
Hubble Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hubble Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hubble Therapeutics in its N-PORT filings yet. We sweep new filings monthly.